BridgeBio Pharma Announces U.S. Food and Drug Administration (FDA) Acceptance of New Drug Application (NDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

February 5, 2024

https://www.globenewswire.com/news-release/2024/02/05/2823433/0/en/BridgeBio-Pharma-Announces-U-S-Food-and-Drug-Administration-FDA-Acceptance-of-New-Drug-Application-NDA-for-Acoramidis-for-the-Treatment-of-Patients-with-Transthyretin-Amyloid-Cardi.html

– Accepted with Prescription Drug User Fee Act (PDUFA) action date of November 29, 2024; FDA not currently planning to hold an advisory committee meeting to discuss application

Read more at globenewswire.com

Related news for (BBIO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.